Avalyn Pharma
Avalyn Pharma Inc is an American clinical-stage biopharmaceutical company developing inhaled therapies for rare lung diseases. The company focuses on reformulating approved systemic drugs into aerosolized formulations, advancing lead candidates including AP01 (inhaled pirfenidone) for idiopathic pulmonary fibrosis. Main revenue drivers currently comprise investment capital financing, research grants, and development partnerships as clinical trials progress. Avalyn Pharma targets pulmonologists, rare respiratory disease clinics, academic research centers, and patients with interstitial lung diseases across North America. The company holds an innovative niche position in inhaled drug delivery for fibrotic lung conditions. Headquartered in Seattle, Washington, Avalyn Pharma Inc operates as a private company.
3 of the funds FundTelligence covers report a position in Avalyn Pharma.
- Legal name
- Avalyn Pharma Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Avalyn Pharma
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.29 % (full portfolio disclosed, September 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.08 % (full portfolio disclosed, September 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)